<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04504760</url>
  </required_header>
  <id_info>
    <org_study_id>ONO-2910-01</org_study_id>
    <nct_id>NCT04504760</nct_id>
  </id_info>
  <brief_title>Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability and PK of ONO-2910 in Japanese and Caucasian Subjects</brief_title>
  <official_title>Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability and PK of ONO-2910 in Japanese and Caucasian Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ono Pharmaceutical Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ono Pharmaceutical Co. Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate safety, tolerability and pharmacokinetics in Japanese and Caucasian subjects&#xD;
      when ONO-2910 is administered as single and multiple doses orally.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is the First in Human (FIH) study to investigate safety, tolerability and&#xD;
      pharmacokinetics in healthy Japanese and Caucasian adult male subjects when ONO-2910 is&#xD;
      administered as single and multiple doses orally. Also, the purpose of this study is to&#xD;
      evaluate pharmacokinetics of oral single-dose of ONO-2910 in Japanese elderly male and female&#xD;
      subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 10, 2020</start_date>
  <completion_date type="Actual">March 18, 2021</completion_date>
  <primary_completion_date type="Actual">March 18, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events [Safety and Tolerability]</measure>
    <time_frame>Up to 13 days</time_frame>
    <description>Number of participants with adverse events as assessed by CTCAE v5.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax [Pharmacokinetic]</measure>
    <time_frame>Up to 10 days</time_frame>
    <description>Assessment of the Cmax of ONO-2910</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax [Pharmacokinetic]</measure>
    <time_frame>Up to 10 days</time_frame>
    <description>Assessment of the Tmax of ONO-2910</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC24h [Pharmacokinetic]</measure>
    <time_frame>Up to 10 days</time_frame>
    <description>Assessment of the AUC24h of ONO-2910</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast [Pharmacokinetic]</measure>
    <time_frame>Up to 10 days</time_frame>
    <description>Assessment of the AUClast of ONO-2910</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf [Pharmacokinetic]</measure>
    <time_frame>Up to 10 days</time_frame>
    <description>Assessment of the AUCinf of ONO-2910</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 [Pharmacokinetic]</measure>
    <time_frame>Up to 10 days</time_frame>
    <description>Assessment of the T1/2 of ONO-2910</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F [Pharmacokinetic]</measure>
    <time_frame>Up to 10 days</time_frame>
    <description>Assessment of the CL/F of ONO-2910</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fe [Pharmacokinetic]</measure>
    <time_frame>Up to 4 days</time_frame>
    <description>Assessment of the Vss of ONO-2910</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLr [Pharmacokinetic]</measure>
    <time_frame>Up to 4 days</time_frame>
    <description>Assessment of the CLr of ONO-2910</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>ONO-2910 (Part A and B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Part A)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ONO-2910 (Part C and D)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Part C and D)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ONO-2910</intervention_name>
    <description>Single ascending dose of ONO-2910 will be administered orally.</description>
    <arm_group_label>ONO-2910 (Part A and B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single dose of placebo will be administered orally.</description>
    <arm_group_label>Placebo (Part A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ONO-2910</intervention_name>
    <description>Multiple ascending dose of ONO-2910 will be administered orally.</description>
    <arm_group_label>ONO-2910 (Part C and D)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Multiple dose of placebo will be administered orally.</description>
    <arm_group_label>Placebo (Part C and D)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Japanese healthy adult male subjects (Part A and C)&#xD;
&#xD;
          2. Japanese men or women after menopause aged ≥65 years and ≤74 years (Part B)&#xD;
&#xD;
          3. Caucasian healthy adult male subjects (Part D)&#xD;
&#xD;
          4. Age (at the time of informed consent): ≥20 years, ≤ 45 years (Part A, C and D)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects currently with or with a history of disease&#xD;
&#xD;
          2. Subjects with current or with a history of severe allergy to drugs or foods&#xD;
&#xD;
          3. Subjects with current or with a history of drug or alcohol abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Masaharu Komeno</last_name>
    <role>Study Director</role>
    <affiliation>Ono Pharmaceutical Co. Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tokyo Clinical Site 01</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>July 31, 2020</study_first_submitted>
  <study_first_submitted_qc>August 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2020</study_first_posted>
  <last_update_submitted>May 13, 2021</last_update_submitted>
  <last_update_submitted_qc>May 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>https://www.ono.co.jp/eng/rd/policy.html</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

